- Home
- CGC vs AURA Comparison
CGC vs AURA Comparison
Compare CGC & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGC | AURA |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.4M | 396.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CGC | AURA |
|---|---|---|
| Price | $1.15 | $6.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | N/A | ★ $20.33 |
| AVG Volume (30 Days) | ★ 22.0M | 200.9K |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $200,022,256.00 | N/A |
| Revenue This Year | $6.79 | N/A |
| Revenue Next Year | $7.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.77 | $4.35 |
| 52 Week High | $3.86 | $9.14 |
Technical Indicators
Market Signals| Indicator | CGC | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 60.80 |
| Support Level | $1.10 | $5.89 |
| Resistance Level | $1.23 | $6.53 |
| Average True Range (ATR) | 0.08 | 0.33 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 63.11 | 86.21 |
Price Performance
Historical ComparisonAbout CGC Canopy Growth Corporation
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.